Nebulised Drug Development Considerations

In this bite-sized article our Formulation and Manufacturing Lead, David Ward, shares some considerations for successful development of nebulised drugs.

Like Comment

Nebuliser delivery of drugs offers a patient-friendly means of transforming a medicine into a breathable aerosol. They offer the advantage, over other types of inhaled device (such as pMDIs or DPIs), in that they do not require such strict patient coordination between inhalation and actuation, and so they are effective for the treatment of paediatric, elderly, ventilated and sedated patients. Intertek Melbourn have been supporting clients’ product development for nearly 30 years across all classes of inhaled and nasal delivery technologies including nebulised therapeutics. 

To access the article, download here:
https://www.intertek.com/pharmaceutical/blog-nebulised-drug-development-considerations/

Go to the profile of Intertek Melbourn

Intertek Melbourn

Intertek Melbourn has specialist skills and experience in analytical testing and formulation for both small molecule and biologic orally inhaled and nasal drug products (OINDP), alongside all other pharmaceutical dosage forms. With 30 years of experience in supporting our clients’ inhaled and nasal product developments, we deliver world-class support for method development / validation, analytical testing, stability programs, CMC studies, formulation development and clinical manufacturing from our facility located in Melbourn, near Cambridge, UK. Our team of scientists have a reputation for providing outstanding and responsive customer service and we have recently announced a significant expansion to double our laboratory footprint and further increase our capacity and flexibility. Through our expertise in analytical and formulation support for the pharmaceutical, biotechnology and drug delivery industries, we help our clients to meet milestones for their challenging pharmaceutical development programmes. The laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The Laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections. • Method Development / Validation • Analytical Testing • Formulation Development • Device Screening • Quality by Design (QbD) Studies • ICH and Accelerated Stability Studies • Clinical Trials Materials Manufacturing • Product Characterisation Studies • In-Vitro Bioequivalence Studies for Generic Products
4 Contributions
0 Followers
0 Following

No comments yet.